These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 1628691

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest.
    el-Raghy I, Back DJ, Makeram M, Salem H, Osman F, Fathalla M, Orme ML.
    Contraception; 1986 Apr; 33(4):379-84. PubMed ID: 3089683
    [Abstract] [Full Text] [Related]

  • 23. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Hammond GL, Langley MS, Robinson PA, Nummi S, Lund L.
    Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.
    Kuhnz W, al-Yacoub G, Power J, Ormesher SE, Back DJ, Jütting G.
    Arzneimittelforschung; 1992 Sep; 42(9):1142-6. PubMed ID: 1445483
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
    Kuhnz W, Schütt B, Power J, Back DJ.
    Arzneimittelforschung; 1992 Sep; 42(9):1139-41. PubMed ID: 1445482
    [Abstract] [Full Text] [Related]

  • 26. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
    Dibbelt L, Knuppen R, Jütting G, Heimann S, Klipping CO, Parikka-Olexik H.
    Contraception; 1991 Jan; 43(1):1-21. PubMed ID: 1825969
    [Abstract] [Full Text] [Related]

  • 27. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
    DiLiberti CE, O'Leary CM, Hendy CH, Waters DH, Margolis MB.
    Contraception; 2011 Jan; 83(1):55-61. PubMed ID: 21134504
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Hormonal and nonhormonal factors affecting sex hormone-binding globulin levels in blood.
    Thijssen JH.
    Ann N Y Acad Sci; 1988 Jan; 538():280-6. PubMed ID: 3056190
    [Abstract] [Full Text] [Related]

  • 31. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Goldstein H, Jespersen J.
    Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics of gestagens: some problems.
    Fotherby K.
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):323-8. PubMed ID: 2115297
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics of levonorgestrel in 18 women after 1 month of treatment with a triphasic oral contraceptive.
    Kuhnz W, al-Yacoub G.
    Horm Res; 1991 Jul; 35(5):178-81. PubMed ID: 1802819
    [Abstract] [Full Text] [Related]

  • 34. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives.
    Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, Ylöstalo P.
    Acta Derm Venereol; 1984 Jul; 64(6):517-23. PubMed ID: 6084924
    [Abstract] [Full Text] [Related]

  • 35. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
    Macha S, Mattheus M, Pinnetti S, Woerle HJ, Broedl UC.
    Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
    [Abstract] [Full Text] [Related]

  • 36. Estimating systemic exposure to levonorgestrel from an oral contraceptive.
    Basaraba CN, Westhoff CL, Pike MC, Nandakumar R, Cremers S.
    Contraception; 2017 Apr; 95(4):398-404. PubMed ID: 28041990
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers.
    Xin X, Wu Y, Liu X, Sun C, Geng T, Ding L.
    Drug Res (Stuttg); 2016 Feb; 66(2):100-6. PubMed ID: 26037079
    [Abstract] [Full Text] [Related]

  • 38. A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
    Darwish M, Bond M, Ricciotti N, Hsieh J, Fiedler-Kelly J, Grasela T.
    Reprod Sci; 2014 Nov; 21(11):1401-10. PubMed ID: 24647707
    [Abstract] [Full Text] [Related]

  • 39. Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol.
    Rogers SM, Back DJ, Stevenson PJ, Grimmer SF, Orme ML.
    Br J Clin Pharmacol; 1987 Jun; 23(6):721-5. PubMed ID: 3111513
    [Abstract] [Full Text] [Related]

  • 40. Influence of losigamone on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers.
    Dienel A, Klement S, Müller F.
    Arzneimittelforschung; 2004 Jun; 54(3):152-9. PubMed ID: 15112861
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.